Abnova Taiwan Corp - Asset Resilience Ratio
Abnova Taiwan Corp (4133) has an Asset Resilience Ratio of 0.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Abnova Taiwan Corp total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2022)
This chart shows how Abnova Taiwan Corp's Asset Resilience Ratio has changed over time. See 4133 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Abnova Taiwan Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abnova Taiwan Corp (4133) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$878.00K | 0.07% |
| Total Liquid Assets | NT$878.00K | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Abnova Taiwan Corp maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Abnova Taiwan Corp Industry Peers by Asset Resilience Ratio
Compare Abnova Taiwan Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Abnova Taiwan Corp (2008–2022)
The table below shows the annual Asset Resilience Ratio data for Abnova Taiwan Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.06% | NT$849.00K ≈ $26.75K |
NT$1.37 Billion ≈ $43.31 Million |
+0.02pp |
| 2021-12-31 | 0.04% | NT$545.00K ≈ $17.17K |
NT$1.28 Billion ≈ $40.42 Million |
+0.00pp |
| 2020-12-31 | 0.04% | NT$543.00K ≈ $17.11K |
NT$1.29 Billion ≈ $40.79 Million |
0.00pp |
| 2019-12-31 | 0.04% | NT$540.00K ≈ $17.01K |
NT$1.26 Billion ≈ $39.82 Million |
+0.00pp |
| 2018-12-31 | 0.04% | NT$537.00K ≈ $16.92K |
NT$1.29 Billion ≈ $40.80 Million |
+0.00pp |
| 2017-12-31 | 0.04% | NT$533.00K ≈ $16.79K |
NT$1.30 Billion ≈ $41.08 Million |
-5.50pp |
| 2016-12-31 | 5.54% | NT$69.11 Million ≈ $2.18 Million |
NT$1.25 Billion ≈ $39.33 Million |
-10.15pp |
| 2015-12-31 | 15.69% | NT$195.97 Million ≈ $6.17 Million |
NT$1.25 Billion ≈ $39.35 Million |
+15.65pp |
| 2014-12-31 | 0.04% | NT$522.00K ≈ $16.45K |
NT$1.31 Billion ≈ $41.21 Million |
0.00pp |
| 2013-12-31 | 0.04% | NT$517.00K ≈ $16.29K |
NT$1.29 Billion ≈ $40.49 Million |
+0.00pp |
| 2012-12-31 | 0.04% | NT$513.00K ≈ $16.16K |
NT$1.29 Billion ≈ $40.71 Million |
+0.00pp |
| 2011-12-31 | 0.04% | NT$508.00K ≈ $16.00K |
NT$1.36 Billion ≈ $42.70 Million |
0.00pp |
| 2010-12-31 | 0.04% | NT$504.00K ≈ $15.88K |
NT$1.33 Billion ≈ $42.03 Million |
-1.09pp |
| 2009-12-31 | 1.13% | NT$14.72 Million ≈ $463.73K |
NT$1.31 Billion ≈ $41.13 Million |
-0.07pp |
| 2008-12-31 | 1.20% | NT$10.26 Million ≈ $323.21K |
NT$857.02 Million ≈ $27.00 Million |
-- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag… Read more